Difference between revisions of "Talazoparib (Talzenna)"
Jump to navigation
Jump to search
m |
m |
||
| Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Breast_cancer,_BRCA-mutated|BRCA-mutated breast cancer]] | *[[Breast_cancer,_BRCA-mutated|BRCA-mutated breast cancer]] | ||
| + | *[[Prostate cancer]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*2018-10-16: Initial approval for patients with deleterious or suspected deleterious [[Biomarkers#Germline|germline]] [[Biomarkers#BRCA|BRCA]]-[[Biomarkers#Alterations|mutated]] (gBRCAm), [[Biomarkers#ERBB2|HER2]]-[[Biomarkers#negative|negative]] locally advanced or metastatic [[breast cancer]]. ''(Based on EMBRACA)'' | *2018-10-16: Initial approval for patients with deleterious or suspected deleterious [[Biomarkers#Germline|germline]] [[Biomarkers#BRCA|BRCA]]-[[Biomarkers#Alterations|mutated]] (gBRCAm), [[Biomarkers#ERBB2|HER2]]-[[Biomarkers#negative|negative]] locally advanced or metastatic [[breast cancer]]. ''(Based on EMBRACA)'' | ||
| + | *2023-06-20: Approved with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant [[prostate cancer]] (mCRPC). ''(Based on TALAPRO-2)'' | ||
| + | |||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2019-06-20: Initial authorization as Talzenna | *2019-06-20: Initial authorization as Talzenna | ||
| Line 21: | Line 24: | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| + | [[Category:Prostate cancer medications]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
[[Category:EMA approved in 2019]] | [[Category:EMA approved in 2019]] | ||
[[Category:Pfizer product]] | [[Category:Pfizer product]] | ||
Revision as of 02:01, 22 June 2023
Mechanism of action
PARP inhibitor
Diseases for which it is used
History of changes in FDA indication
- 2018-10-16: Initial approval for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. (Based on EMBRACA)
- 2023-06-20: Approved with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Based on TALAPRO-2)
History of changes in EMA indication
- 2019-06-20: Initial authorization as Talzenna
- Uncertain date: Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.
Also known as
- Code name: BMN-673
- Brand name: Talzenna